The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of ...

Despite a short time on the market, Mounjaro and Zepbound have become key top-line ... in 2024 has been impacted by supply and channel dynamics. In the second quarter, increased supply led to ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

such as Ozempic and Zepbound. Some economists and talking heads insist that the highly regulated healthcare sector is immune to price signals and other market dynamics due to its unique structure ...

Although Novo was first to market with Wegovy and its sister drug Ozempic for diabetes, Lilly has gained the lead in obesity prescriptions with Zepbound. The US company’s diabetes version of the ...

A previous version of this report failed to reflect that the scientific name tirzepatide refers to Zepbound. It has been corrected. A study of two blockbuster weight-loss drugs showed that users ...

Despite being on the market for less than three years, Mounjaro and Zepbound became key top-line ... than-expected growth and unfavorable channel dynamics, their sales picked up in the first ...